Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer
October 04 2019 - 4:59PM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)
today announced the appointment of Klaus Paulini as President and
Chief Executive Officer of the Company, effective today, replacing
Michael Ward. Dr. Paulini will also serve as a Director of the
Company.
Dr. Paulini will continue to be based in
Frankfurt, Germany, and his appointment as President and Chief
Executive Officer aligns with the Company’s refocus on its
operations in Germany. The Company’s registered office will remain
in Toronto, Ontario, Canada.
Dr. Paulini began his career in the
pharmaceutical industry at ASTA Medica AG in 1997. He had an active
role in the spinoff and formation of Aeterna Zentaris GmbH from
ASTA Medica. Dr. Paulini has managed many of the Company’s clinical
development projects including research and development of
Macrilen™ (macimorelin). Dr. Paulini obtained his PhD (Dr. Ing.) in
chemistry at the Technical University Darmstadt (Germany) in 1993
and specialized in medicinal chemistry and drug discovery during
subsequent postdoctoral fellowships at Strathclyde University
(Glasgow, Scotland) and J.W. Goethe University (Frankfurt,
Germany).
The board of directors of the Company thanks Mr.
Ward for his contribution to the Company and wishes him all the
best in the future.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company engaged in commercializing novel
pharmaceutical therapies, principally through out-licensing
arrangements. Aeterna Zentaris is the licensor and party to a
license and assignment agreement with Novo Nordisk A/S to carry out
development, manufacturing, registration, regulatory, and supply
chain for the commercialization of Macrilen™ (macimorelin), which
is to be used in the diagnosis of patients with adult growth
hormone deficiency in the United States and Canada. In addition, we
are actively pursuing business development opportunities for
macimorelin in the rest of the world and to monetize the value of
our non-strategic assets.
Contact:Leslie AuldChief Financial
OfficerAeterna Zentaris Inc.IR@aezsinc.com(843) 900-3211
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024